BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dengue readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Dengue\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06006559-11254@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:EYU688: Phase 2 readout est. (NCT06006559)
DESCRIPTION:EYU688\, phase 2\, Dengue.\nStudy: A Study to Assess the Effica
 cy\, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever\n
 Estimated primary completion: 22 July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/eyu688#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06006559
URL:https://assetmemo.bio/drug/eyu688#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013487-11240@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20310906
DTEND;VALUE=DATE:20310907
SUMMARY:V181: Phase 3 readout est. (NCT07013487)
DESCRIPTION:V181\, phase 3\, Dengue.\nStudy: A Study to Evaluate V181 Dengu
 e Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-
 1)\nEstimated primary completion: 6 September 2031. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/v181#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07013487
URL:https://assetmemo.bio/drug/v181#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
